SCHEMBL5779855

SCHEMBL5779855

O=C(Nc1cccc2c1CN(Cc1cccc(C[SiH3])c1)C2=O)c1ccc(Cl)s1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.73
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HDAC1 Q13547 2/20 0.39
ACKR3 P25106 1/20 0.39
STK33 Q9BYT3 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
DHPS P49366 1/20 0.38
PRSS12 P56730 1/20 0.38
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 1/20 0.35
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5777469 0.92 F10 (0.74) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5779422 0.91 F10 (0.73) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5784059 0.90 F10 (0.72) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL3376377 0.90 F10 (0.74) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5782623 0.89 F10 (0.76) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5782214 0.88 F10 (0.70) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5781275 0.88 F10 (0.70) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5784719 0.88 F10 (0.74) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5783650 0.87 F10 (0.69) F10ALDH1A1HPGDSMN1; SMN2HDAC1
SCHEMBL5779069 0.87 F10 (0.68) F10ALDH1A1HPGDSMN1; SMN2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408962-B1 SUBSTITUTED ISOINDOLES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2006-03-15 EP disclosed
US-6933295-B2 Substituted isoindoles and the use thereof BAYER AKTIENGESELLSCHAFT (DE) 2005-08-23 US disclosed
US-20050004207-A1 Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-01-06 US disclosed
EP-1408962-A1 SUBSTITUTED ISOINDOLES AND THE USE THEREOF Bayer HealthCare AG (DE) 2004-04-21 EP disclosed
WO-2003007942-A1 SUBSTITUTED ISOINDOLES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004207-A1 Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders F2, SERPINC1, F11 F10 4/4885ALDH1A1 1523/4885HPGD 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.